$GOSS

Gossamer Bio reported Q2 2026 net income of $16.9M and cash, cash equivalents and marketable securities of $57.0M as of June 30, 2026, citing non-operating gains from debt extinguishment. Revenue from collaborators was $9.2M. The company said it plans to submit an NDA for seralutinib in PAH in Sept 2026 and received FDA Pre-NDA Type B minutes. Shareholders approved a convertible note exchange and a potential reverse stock split.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 goss-20260813xexx991xearni.htm EX-99.1 Document Exhibit 99.1 Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - NDA Submission for Seralutinib in PAH On Track for September 2026 Following Receipt of Pre-NDA Type B Meeting Minutes

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 2 goss-20260727xex101xchiesi.htm EX-10.1 Document Exhibit 10.1 EXECUTION VERSION RIGHTS REACQUISITION AGREEMENT This RIGHTS REACQUISITION AGREEMENT (this “ Agreement ”) is entered into as of July 23, 2026 (the “ Rights Reacquisition Effective Date ”), by and among Chiesi

Gossamer Bio (NASDAQ:GOSS) said it restructured debt by exchanging 5.00% convertible notes due 2027, cutting principal by about $115.9 million to $18.9 million, and authorized a reverse stock split. It ended its collaboration with Chiesi to regain full global rights to its PAH lead candidate, with a $5 million one-time payment from Chiesi. Gossamer Bio expects an FDA NDA decision in Q3 2027 if accepted.

Gossamer Bio (GOSS) said it received FDA Type B meeting minutes and plans to file an NDA for its investigational inhaled drug seralutinib for pulmonary arterial hypertension in September 2026. If accepted, a decision is expected in Q3 2027. Gossamer reacquired global rights from Chiesi and reported about $57M cash as of June 30, 2026.

Oil fell after a lull in Middle East hostilities and a US pause in strikes against Iran, with September Brent down about 9% to around $88 per barrel. Bond yields and the dollar eased, while US stock futures rose on a relief rally. The article also cites premarket moves in several stocks, including QBTS, F, FBRX, GM, GOSS, and MPLT, plus Argenx buying Forte Biosciences for about $2.2B.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 3 goss-20260714xex101xrest.htm EX-10.1 goss-20260714xex101xrest GOSSAMER BIO, INC. 2019 INCENTIVE AWARD PLAN (As Amended and Restated Effective May 18, 2026) ARTICLE I. PURPOSE The purpose of this amended and restated Plan is to enhance the Company’s ability to attract, r

Hagens Berman said it filed a securities class action against Gossamer Bio (NASDAQ: GOSS) and an executive for investors who bought shares between June 16, 2025 and Feb. 20, 2026. The suit follows Gossamer’s Feb. 23, 2026 announcement that its Phase 3 PROSERA trial for PAH missed the primary endpoint, after which the stock fell about 80%. Lead plaintiff deadline is June 1, 2026.

Faruqi & Faruqi, LLP said it is investigating potential federal securities-law claims against Gossamer Bio (NASDAQ: GOSS) and reminded investors of a June 1, 2026 deadline to seek lead-plaintiff status in a filed class action. The complaint alleges misleading disclosures about Phase 3 PROSERA design and placebo control. After Feb. 23, 2026 topline results showed the trial missed its 6MWD primary endpoint (p=0.0320 vs alpha 0.025), GOSS shares fell from $2.13 to $0.42 in one day.